Takeda Pharmaceutical Company Limited Stock Boerse Muenchen
Stocks
TKDA
US8740602052
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Boerse Muenchen
00:43:58 03/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 15.90 EUR | -0.62% |
|
-3.64% | +21.37% |
| 09-30 | Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading | MT |
| 09-30 | Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial | MT |
| Market Cap | 9,011B 57.13B 50.76B 47.38B 43.18B 81.44B 5,492B 82.2B 573B 222B 2,808B 214B 210B | P/E 2027 * |
44.7x | P/E 2028 * | 28.4x |
|---|---|---|---|---|---|
| Enterprise Value | 12,917B 81.9B 72.77B 67.92B 61.9B 117B 7,873B 118B 822B 318B 4,025B 307B 301B | EV / Sales 2027 * |
2.75x | EV / Sales 2028 * | 2.65x |
| Free-Float |
99.25% | Yield 2027 * |
3.62% | Yield 2028 * | 3.69% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| TAK | Delayed | |
CBOE
| TAK | Real-time | |
|
London S.E.
| 0A87 | Delayed | |
|
Tradegate
| TKDA | Real-time | |
|
Deutsche Boerse AG
| TKDA | Delayed | |
|
Börse Stuttgart
| TKDA | Delayed | |
|
Boerse Muenchen
| TKDA | Real-time |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 week | -3.64% | ||
| Current month | -1.24% | ||
| 1 month | -0.62% | ||
| 3 months | +9.66% | ||
| 6 months | -1.85% | ||
| Current year | +21.37% |
| 1 week | 15.9 |  | 16.9 |
| 1 month | 15.7 | | 16.9 |
| 3 years | 11.3 | | 16.9 |
| 5 years | 11.3 | | 16.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2025 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 01/04/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 61 | 01/06/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 01/01/2019 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 01/06/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.62% | -3.64% | +28.23% | +9.66% | 57.13B | |
| -0.61% | -3.43% | +39.40% | +112.31% | 1,019B | |
| -1.02% | -5.60% | +37.67% | +65.02% | 617B | |
| +1.11% | -0.58% | +11.10% | +77.28% | 464B | |
| +0.34% | -3.01% | +61.21% | +40.71% | 356B | |
| -0.95% | -4.05% | +21.60% | +39.37% | 333B | |
| -1.46% | -2.89% | +11.84% | +24.60% | 267B | |
| -1.35% | -5.43% | -4.69% | +8.40% | 244B | |
| -1.04% | -2.79% | +35.52% | +51.34% | 218B | |
| -1.87% | -4.10% | +30.92% | +95.33% | 179B | |
| Average | -0.23% | -3.39% | +27.28% | +52.40% | 410.8B | |
| Weighted average by Cap. | +0.42% | -3.33% | +30.48% | +68.05% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,704B 29.82B 26.5B 24.73B 22.54B 42.51B 2,867B 42.91B 299B 116B 1,466B 112B 110B | 4,794B 30.4B 27.01B 25.21B 22.98B 43.33B 2,922B 43.73B 305B 118B 1,494B 114B 112B |
| Net income | 196B 1.25B 1.11B 1.03B 942M 1.78B 120B 1.79B 12.5B 4.84B 61.23B 4.68B 4.58B | 323B 2.05B 1.82B 1.7B 1.55B 2.92B 197B 2.94B 20.53B 7.96B 101B 7.68B 7.52B |
| Net Debt | 3,907B 24.77B 22.01B 20.54B 18.72B 35.31B 2,381B 35.64B 249B 96.32B 1,217B 92.99B 90.97B | 3,702B 23.47B 20.86B 19.47B 17.74B 33.46B 2,257B 33.77B 236B 91.28B 1,154B 88.13B 86.22B |
| Date | Price | Change |
|---|---|---|
| 02/10/26 | €15.90 | -0.62% |
| 01/10/26 | €16.00 | -0.62% |
| 30/09/26 | €16.10 | -1.23% |
| 29/09/26 | €16.30 | -1.81% |
| 28/09/26 | €16.60 | +0.61% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
- TKDA Stock
Select your edition
All financial news and data tailored to specific country editions
